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ABSTRACT 
Data from literature show that the overall risk of cancer does not as a result from treatment with these drugs. The only 
cancer for which various authors have reported an increased risk, in some cases, are skin cancers, different from 
melanoma and melanoma. Recent results of large observational studies and meta-analyzes indicate the absence of an 
increased risk of lymphoma related to therapy with anti-TNF-α. It has been reported, by some authors, that there is a 
possible increased risk of lung cancer, especially in patients with chronic obstructive pulmonary disease. There is 
limited information in literature about the effects of biologics in patients with a history of cancer. Most of the guidelines 
indicate that treatment with biologics can be considered with caution and only in patients free of cancer since at least 5 
years. Some studies report a lower oncological risk with etanercept compared to monoclonal antibodies, especially in 
the case of lymphoma. However, this data has not been confirmed in other studies, and has been associated with a 
limited period of time after starting therapy. Information about the latest biological therapies is still poor. Therefore, 
there is not sufficient evidence for a preferential use of certain drugs rather than others. 
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1. Introduction 
In chronic inflammatory diseases that require long-term 
treatment with immunosuppressive therapies, there has 
always been concern that such treatments could increase 
the risk of developing cancer. 
Biological agents acting through complex mechanisms 
of immunomodulation and some cytokines inhibited by 
these treatments (such as TNF-α) exert important biolo- 
gical effects, although not fully defined, which can coun- 
teract the processes of carcinogenesis and tumor progres- 
sion. 
Even if overall data so far issued on cancer risk in pa- 
tients with biological agents are encouraging, it should be 
noted that the assessment of such risk is complicated by a 
number of factors including the following: 1) Rheuma- 
toid Arthritis (RA) gives rise to a differential risk for va- 
rious types of tumors (increased or decreased, in some 
cases) compared to the general population; 2) develop- 
ment period of a neoplasm is often long and it can exceed 
the period of observation of many studies; 3) tumors are 
relatively rare adverse events and the analysis of their 
impact requires data of very large populations, in order to 
achieve a sufficient statistical power; 4) in clinical trials 
enrollment of patients with a history of cancer or high 
risk cancer is usually excluded; 5) in clinical practice 
there may be a bias in the selection of patients for ther- 
apy with biological agents. These issues must be consid- 
ered in interpreting data provided by clinical and obser- 
vational trials. So even if there are no specific contrain- 
dications for the use of biological drugs in relation to the 
risk of cancer, guidelines and consensus statements agree 
to maintain a high level of vigilance for the possible risk 
of developing cancer in patients receiving biologic thera- 
pies. 
2. RA and Malignancies 
Several epidemiological studies show that patients with 
RA, if compared with the general population, have an in- 
creased risk to develop certain type of malignancies, es- 
pecially lymphoma and cancers of the hematopoietic 
system, lung and skin cancer other than melanoma, while 
the risk for colorectal, breast and endometrial cancers 
(lower risk by use of non-steroidal anti inflammatory 
drugs or cyclo-oxygenase-2) is reduced [1-7]. The rela- 
tionship between RA and lymphoma has been investi- 
gated with particular attention. A meta-analysis of stud- 
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ies investigating the risk of overall and four specific ma- 
lignancies in patients with rheumatoid arthritis compared 
with the general population showed a doubled risk of 
lymphoma with a standardized incidence ratio (SIR) of 
2.08 (IC 95% 1.80 - 2.39) [8]. The risk was highest for 
Hodgkin’s lymphoma (SIR 3.29 [95% CI 2.56 - 4.22]) 
compared to a non-Hodgkin’s lymphoma (SIR 1.95 [95% 
CI 1.70 - 2.24]). The risk of developing lung cancer was 
also increased, SIR 1.63 (95% CI 1.43 - 1.87) and the 
risk of developing colorectal or breast cancer was slightly 
reduced in patients with RA, respectively SIR 0.77 (95% 
CI 0.65 - 0.90) and SIR 0.84 (95% CI 0.79 - 0.90) [8]. 
3. Anti-TNF-α and Risk of Malignancies 
The relationship between anti-TNF-α and cancers is not 
fully understood and it is likely that this cytokine plays 
different roles in different stages of tumors and neoplas- 
tic processes. Therefore the inhibition of TNF-α may re- 
sult in various effects on the oncological risk depending 
on the type of tumor and conditions of the patient. As far 
as the overall risk of developing cancer (regardless of the 
type of cancer) is concerned, almost all studies indicate 
that the risk is not increased in patients with RA treated 
with anti-TNF-α compared to the general population or 
control groups that are not exposed to such therapy. An 
overall increase in the incidence of cancers related to bio- 
logics in large observational studies has not been de- 
tected, including those carried out on the national Regis- 
ters (NDB for Rheumatic Diseases for the US, Swedish 
Biologics Register for Sweden, BSRBR for the United 
Kingdom, BIOBADASER for Spain, LOHREN for Italy 
and RABBIT for Germany) and the meta-analyses of 
clinical trials [4,9-17]. Just in another meta-analysis con- 
cerning a clinical trial of infliximab and adalimumab it 
was found that there was a significant increase in the 
overall risk of developing cancer in patients treated with 
biological agents compared to those who were not (OR 
3.3 [95% CI 1.2 to 9.1]) [18]. The increased risk was 
most evident in patients treated with higher doses. It is 
not clear what the main reason for this discrepancy of 
data in relation to other evidence of the literature is due 
to; some authors attribute it to methodological problems 
(such as the possible lack of identification of cases for 
the highest percentage of drop-outs in groups of compa- 
rison) [19]. A meta-analysis of etanercept, made by the 
same group of researchers using methods similar to the 
previous, showed a smaller increase in the risk of cancer 
with etanercept, but this was not significant (HR 1.84 
[95% CI 0.79 to 4.28]) [20]. A recent meta-analysis of 
data presented in studies of registry and prospective ob- 
servational studies confirm that the anti-TNF-α does not 
appear to increase the overall risk of developing cancer, 
with an estimated cumulative risk calculated at 0.95 (95% 
CI 0.85 - 1.05) [21]. An observational study of Askling 
and coll. conducted on a Swedish database has analyzed 
the risk of cancer development in time after initiation of 
anti-TNF-α therapy and the duration of such therapy 
without encountering an increase of the oncological risk 
linked to these two variables [9]. Another study has as- 
sessed whether biological agents could influence the 
prognosis of tumors which have arisen in the course or at 
the end of therapy by examining any changes in clinical 
presentation and the outcome of these malignancies [22]. 
No significant differences were found in the clinical pre- 
sentation of cancers or in the survival among patients 
exposed to anti-TNF-α compared with those not treated 
with the same therapies. 
3.1. Lymphatic and Hematopoietic Tumors 
We cannot define whether anti-TNF-α may increase the 
risk of lymphoma, also due to the difficulty in correctly 
estimating the risk in patients with RA who already have 
an increased risk of lymphoma compared to the general 
population. However, the main observational studies have 
not shown an increased incidence of malignant lym- 
phoma or cancers of the hematopoietic system in patients 
treated with anti-TNF-α compared with cohorts of pa- 
tients with RA or other patients treated with traditional 
drugs (DMARDs) [2,4,15,23,24]. Studies conducted on 
the records of the US NDB for Rheumatic Diseases and 
on the Swedish Biologics Register do not show an in- 
creased risk. In the study conducted by the US on 19,591 
patients with RA (55% were treated with anti-TNF-α) 
between 1998 and 2005, the odds ratio (OR) for lym- 
phoma in patients treated vs those not treated with bio- 
logical agents corresponds to 1.0 (95% CI 0.6 to 1.8) [23]. 
Askling and coll. have reported 500 cases of tumors of 
the hematopoietic system in three Swedish cohorts of 
patients with RA which were analyzed: a cohort study of 
prevalence, a cohort of incidence and a cohort treated 
with anti-TNF-α (n = 4160, 1999-2003) [2]. Patients af- 
fected by RA, compared to the general population, 
showed an increased risk in the development of lym- 
phoma and leukemia. The relative risk (RR) of lym- 
phoma in patients receiving biological therapy compared 
with the cohort prevalence was 1.1 (95% CI 0.6 - 2.1). In 
a subsequent study by the same group which extended 
the follow-up to 2006 by analyzing data on 67,743 pa- 
tients with RA, 26 cases of malignant lymphoma among 
6604 patients treated with anti-TNF-α were observed vs 
336 cases compared to the population not treated with 
these drugs, resulting in an RR of 1.35 (95% CI 0.82 - 
2.11) [24]. The observational study of Geborek and coll. 
detected an increased risk of lymphoma related to anti- 
TNF-α therapy (RR 4.9 [IC 95% 0.9 - 26.2]), but such 
study was conducted on a limited number of cases and 
there is the possibility of methodological issues that may 
have influenced these results [14]. In the prospective  
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study on the RATIO register it is not possible to quantify 
the potential risk of lymphoma associated with the use of 
anti-TNF-α (this registry reports all cases of lymphoma 
occurred in French population in patients receiving these 
therapies, regardless of their disease, between 2004 and 
2006, without a control cohort consisting of patients not 
treated with anti-TNF-α) [25]. Among 38 cases of lym- 
phoma reported, 27 were patients with RA, with a SIR of 
treated patients compared with the general population of 
2.3 (95% CI 1.6 - 3.3), which reflects an increased risk of 
lymphoma in RA related disease activity. Therefore, data 
of major studies give evidence of the absence of an in- 
creased risk of lymphoma or cancer of the hematopoietic 
system related to anti-TNF-α therapy. 
3.2. Solid Tumors 
Treatment with anti-TNF-α does not imply an increase in 
the overall risk of developing solid tumors [3,4,15]. How- 
ever, several observational studies and meta-analyses 
show an increased incidence of skin cancers other than 
melanoma (NMSC) and some cases of melanoma in pa- 
tients treated with biological drugs compared to control 
groups [3,4,16,21,26]. In particular, the study of Wolfe 
and coll. on the US NDB for Rheumatic Diseases has 
found an OR of 1.5 (95% CI 1.2 - 1.8) for NMSC and an 
OR of 2.3 (95% CI 0.9 - 5.4) for melanoma in patients 
treated with anti-TNF-α therapy vs those not exposed to 
such therapy [4]. The study conducted on the Swedish 
registers for NMSC shows a SIR of 3.6 (95% CI 1.50 - 
6.5) in cohorts treated with biologics compared to 1.66 
(95% CI 1.50 - 1.84) in the prevalence cohort [3]. A re- 
cent meta-analysis of clinical trials of infliximab, ada- 
limumab and etanercept shows an increased risk of deve- 
loping NMSC related to therapy with anti-TNF-α [26,16]. 
However not all studies have found an increased risk for 
skin cancer in patients exposed to anti-TNF-α, especially 
if they have chronic bronchitis [11,27]. 
4. Are There Different Effects on the Risk 
Cancer among Anti-TNF-α? 
Some data indicate different effects on the risk of cancer 
among infliximab, adalimumab and etanercept, as only a 
few studies have individually analyzed these three drugs. 
In the study of the French RATIO register which evalu- 
ated the risk of lymphoma in patients treated with anti- 
TNF-α vs the general population, the risk of lymphoma 
with etanercept was lower with a SIR of 0.9 (CI 95% 0.4 
- 1.8), compared with the risk of lymphoma with ada- 
limumab and infliximab [25]. Likely TNF-α inhibitors 
(similarly to methotrexate) exert a double effect on the 
risk of lymphoma: a beneficial effect which reduces the 
disease’s activity and a detrimental one which depresses 
the immunosurveillance by the lymphocytes T; in the case 
of etanercept the prevailing effect would appear favor- 
able. One hypothesis to explain the lower incidence of 
lymphoma observed with etanercept (a soluble fusion 
protein) compared to monoclonal antibodies, is probably 
due to the higher affinity and stability of binding to the 
TNF-α membrane with respect to infliximab and adali- 
mumab, which would lead to stronger effects on the 
function of immune surveillance by T suppressor lym- 
phocyte compared to etanercept [35]. Also in the meta- 
analysis by Bongartz and coll., the overall cancer risk 
found in studies of adalimumab and infliximab was su- 
perior to that observed in studies of etanercept [18,20]. In 
a study of Swedish registers, differences were observed 
between the three anti-TNF-α on the overall risk of de- 
veloping cancer but only during the first year after the 
start of biological therapy [9]. It is not clear why differ- 
ences between drugs are found only at the beginning of 
treatment; this could be determined by actual differences 
in the biological activity but also by other external fac- 
tors that are difficult to control in an observational study. 
There are no significant differences identified between 
anti-TNF-α therapies on the risk of malignancy in the va- 
rious locations in the studies on the US NDB for Rheu- 
matic Diseases [4,23]. Therefore the question whether 
etanercept, infliximab, adalimumab are more or less as- 
sociated with clinically significant differences in the risk 
of developing cancer remains controversial. 
5. Effects of Treatment with Anti-TNF-α 
Therapy in Patients with a History of 
Cancer 
There is limited information concerning the risk of can- 
cer related to therapy with biologic drugs in RA patients 
previously affected by cancer as these patients are gene- 
rally excluded from clinical trials. Moreover, guidelines 
often advise particular caution in the use of these the- 
rapies in patients with a history of malignancy. An ob- 
servational study evaluated the incidence of tumors in 
239 patients enrolled in the British register BSRBR in 
which a malignancy had been reported (except carcinoma 
in situ and NMSC) [10]; 177 patients had received ther- 
apy with anti-TNF-α and 117 were treated with DM- 
ARDs. During a follow-up of 3 years the mean incidence 
of cancer was 25.3 events/1000 patient-years in the co- 
hort treated with biologics vs 38.3/1000 patient-years in 
the comparison group, with an incidence rate ratio (IRR) 
of 0.58 (95% CI 0.23 - 1.43) for patients treated with 
anti-TNF-α vs DMARDs. A sensitivity analysis made 
with the exclusion of time from the first tumor did not 
significantly alter this data; such data also indicate that 
patients with a previous diagnosis of melanoma may 
have a higher risk of developing a new cancer. Accord- 
ing to the results of this study the risk of malignancy in  
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patients with a tumor does not seem to be increased by 
previous therapy with biological drugs. However, it is 
important to consider a possible selection bias in the 
choice of treatment to be applied to patients, which could 
have influenced results of this investigation. Even in the 
study of the German register RABBIT, the risk of recur- 
rence of earlier tumors in 122 patients, of whom 58 re- 
ceived anti-TNF-α, 9 anakinra and 55 DMARDs was 
analyzed [13]; fifteen occurrences of cancer were re- 
ported in 14 patients and the IRR between anti-TNF-α 
and DMARDs was 1.4 (p = ns). Also in this study the 
limited series does not allow definitive conclusions about 
the risk of cancer linked to biological therapies in pa- 
tients with a previous malignancy. 
6. Cancer Risk with Other Biologics Drugs 
Data concerning biological drugs with a different mecha- 
nism of action than that of anti-TNF-α (as well as new 
generation anti-TNF-α) for an assessment of the risk of 
cancer are still limited. The information derives mainly 
from clinical trials and there are still no data about safety 
from large observational studies. There was no reported 
increased risk of solid tumors or lymphoma with ritu- 
ximab [28]. As far as the risk of developing lymphoma in 
patients with rheumatoid arthritis is concerned, the studies 
of Slimani [29] and van Vollenhoven’s [30] would sug- 
gest a protective role of rituximab. In the clinical de- 
velopment program of abatacept (which includes 4134 
patients treated with this drug in clinical trials and 41,529 
in observational studies), 51 tumors were reported and 
the overall incidence of cancer (excluding NMSC) and of 
four types of tumor evaluated (breast, colorectal, lung 
and lymphoma) in patients treated with abatacept was 
generally similar to that found in populations affected by 
RA [31]. Similarly, there were no problems linked to the 
possibility of an increased risk of tumors in studies on 
tocilizumab. An interim post marketing surveillance ana- 
lysis of 3881 patients treated with tocilizumab showed an 
incidence rate of malignancy of 18 events year/100 pa- 
tients [32]. 
7. Discussion 
It is difficult define whether anti-TNF-α may increase the 
risk of lymphoma in RA because patients with RA al- 
ready have an increased risk of lymphoma compared to 
the general population. However, the main observational 
studies have not shown an increased incidence of malig- 
nant lymphoma probably because the main risk factor for 
lymphoma seems to lie in the severity of the disease, as 
demonstrated in a case-control study conducted on the 
Swedish Inpatient Register during 1964-1995 that showed 
a direct correlation between disease activity and the risk 
of lymphoma, with an increase of the latter in the sub- 
group of patients with the highest activity of disease [33]. 
Therefore chronic inflammation plays a key role in the 
risk of lymphoma. In order to explain this effect it was 
assumed that in RA persistent immune stimulation can 
lead to a clonal selection in B lymphocytes inducing ma- 
lignant transformation in CD5+ cells and reduce the num- 
ber and functional activity of T suppressor lymphocytes 
(like those directed against the oncogenic virus, Epstein- 
Barr) [8]. Another study of the Swedish group investi- 
gated the possibility of a common genetic susceptibility 
for the development of lymphoma and RA, evaluating 
whether the increased risk of lymphoma was detectable 
even before diagnosis of RA [34]. It was observed that 
the risk increased only in the ten years following the di- 
agnosis of RA, confirming the importance of the disease 
as a determining factor for the increased risk of lym- 
phoma. It was not always possible to assess the actual 
role of therapy as the risk of cancer related to RA was 
calculated on populations treated with different therapies. 
Unlike some immunosuppressive agents, such as azathio- 
prine for which an association with lymphoma has been 
highlighted, therapy with DMARDs seems not to be as- 
sociated with an increased risk of lymphoma, even though 
cases of EBV-positive lymphoma were reported in pa- 
tients treated with methotrexate, which regressed after 
discontinuation of the drug [33-35]. The potential effect 
of induction of EBV-related lymphomas by methotrexate 
is probably outset by the beneficial effect of this drug on 
the reduction of disease activity with a favorable result, 
as potential effect of induction of anti-TNF-α related 
lymphomas is outset by efficacy of these drugs on sever- 
ity of the disease and chronic inflammation [35]. 
8. Conclusion 
Patients starting anti-TNF-α therapy should be informed 
that there is no conclusive evidence for an increase in 
risk of developing solid tumors or lymphomas above that 
which would be expected for RA population, but ongoing 
vigilance is required. Patients should be investigated for 
potential malignancy if clinically suspected, and anti- 
TNF-α treatment should be stopped if malignancy is con- 
firmed. Caution should be exercised in the use of these 
therapies in patients with previous malignancy. Patients 
should be advised that the treatment with anti-TNF-α 
may increase the risk of non-melanoma skin cancer and it 
is necessary preventative skin care and continuous skin 
surveillance. There are no significant differences identi- 
fied between anti-TNF-α therapies on the risk of malig- 
nancy. 
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